Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy

This post-hoc analysis of a randomized, placebo-controlled trial aimed to assess whether the risk of bronchopulmonary adverse events was reduced with idebenone versus placebo in 64 patients with Duchenne muscular dystrophy. Standard spirometry was performed using a Vitalograph Pneumotrac Spirometer to measure FVC and PEF.